drugset / Trial / NCT05597202
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
Phase 4
Unknown
22 enrolled
Academic Medical Center - University of Amsterdam
Dutch Heart Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
To study the effect of type 2 diabetes (T2D) on vascular wall inflammation and hematopoietic stem cell composition in vivo, and whether these changes can be reversed with glucagon like peptide 1 receptor (GLP1R)-agonism.
Timeline
- Start
- 2023-01-01
- Primary completion
- 2024-03
- Completion
- 2024-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 2 mg | Subcutaneous |